GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

The changes in goodwill for the three months ended March 31, 2017 and for the year ended December 31, 2016 were as follows:



	March 31, 2017		December 31, 2016
Balance, beginning of period	$	6,000	$	5,905
Goodwill acquired during the period	1		95
Balance, end of period	$	6,001	$	6,000

Principally all of the Company’s goodwill as of March 31, 2017 and December 31, 2016 was associated with its DIS business.

For the year ended December 31, 2016, goodwill acquired was principally associated with the acquisition of the outreach laboratory service business of Clinical Laboratory Partners, LLC.

Intangible assets at March 31, 2017 and December 31, 2016 consisted of the following:



	Weighted Average Amortization Period (in years)	March 31, 2017							December 31, 2016
	Weighted Average Amortization Period (in years)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Amortizing intangible assets:
Customer-related	18	$	971	$	(359	)	$	612	$	971	$	(346	)	$	625
Non-compete agreements	6	7		(5		)	2		6		(4		)	2
Technology	18	93		(41		)	52		93		(40		)	53
Other	9	103		(72		)	31		103		(70		)	33
Total	18	1,174		(477		)	697		1,173		(460		)	713

Intangible assets not subject to amortization:
Trade names		235		—			235		235		—			235
Other		1		—			1		1		—			1
Total intangible assets		$	1,410	$	(477	)	$	933	$	1,409	$	(460	)	$	949

Amortization expense related to intangible assets was $17 million and $19 million for the three months ended March 31, 2017 and 2016, respectively.

The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2017 is as follows:



Year Ending December 31,
Remainder of 2017	$	52
2018	65
2019	64
2020	64
2021	58
2022	55
Thereafter	339
Total	$	697

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details